{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:42:12Z","timestamp":1772764932525,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The introduction of immune-checkpoint inhibitors (ICPI) in recent years has changed the natural course of many neoplasms. However, patients receiving these medications may present immune-mediated adverse events; management includes temporary or permanent cessation of treatment and corticosteroids, occasionally combined with other immunomodulators. Such immunosuppression, however, also has numerous adverse events and even if it is effective in controlling toxicity, it delays immunotherapy reinitiation, as current evidence requires dose tapering to\u2005\u226410\u2009mg prednisolone equivalent before rechallenge. Enteric-coated budesonide is a corticosteroid formulation acting primarily to the intestine and liver, as a result of its extensive first-pass hepatic metabolism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 76-year-old woman treated with ipilimumab for metastatic melanoma presented with abdominal pain, vomiting, and diarrhea for at least the previous 4 days. Laboratory tests, among others, revealed elevated aminotransferases and C-reactive protein. During hospitalization, the patient also developed fever.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient, after excluding alternative causes of aminotransferase elevation, was diagnosed with grade 3 ipilimumab-associated hepatotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Budesonide monotherapy was administered; initial daily dose was 12\u2009mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Fever subsided after the first dose of budesonide. Aminotransferases returned to normal-near normal approximately 1 month after the first dose of budesonide. After this point, daily dose was reduced by 3\u2009mg every 2 weeks, with no clinical or biochemical relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case of ICPI hepatitis is, to our knowledge, the first in the literature managed with budesonide monotherapy. Therefore, budesonide may be a potentially attractive option for the management of ICPI-associated liver injury in cases where corticosteroid treatment is necessary due to its safety profile and the potential advantage of faster immunotherapy rechallenge in selected patients without requiring dose tapering, in contrast to systemically acting corticosteroids. Clinical trials should be conducted in the future in order to validate or refute these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029473","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:00:39Z","timestamp":1660053639000},"page":"e29473","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-2855","authenticated-orcid":false,"given":"Gerasimos","family":"Eleftheriotis","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine, General Hospital of Nikaia-Piraeus \u201cAgios Panteleimon,\u201d Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Skopelitis","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine, General Hospital of Nikaia-Piraeus \u201cAgios Panteleimon,\u201d Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl_4","key":"R1-20250504","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor (ICI) colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","article-title":"Autoimmune hepatitis\u2014update 2015","volume":"62","author":"Manns","year":"2015","journal-title":"J Hepatol"},{"key":"R5-20250504","first-page":"1","article-title":"Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis","volume":"32","author":"Dalekos","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20250504","first-page":"803","article-title":"Pharmacokinetics of budesonide (Entocort\u2122 EC) capsules for Crohn\u2019s disease","volume":"43","author":"Edsb\u00e4cker","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisolone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0002-9270(02)05282-6","article-title":"Systemic exposure and availability of orally administered budesonide capsules (Entocort\u2122 EC) vs methylprednisolone [abstract]","volume":"97","author":"Edsb\u00e4cker","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","article-title":"Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis","volume":"41","author":"Everett","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn\u2019s disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"R26-20250504","article-title":"European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations","volume":"9:13","author":"Miehlke","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1824645","DOI":"10.1080\/2162402X.2020.1824645","article-title":"Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma","volume":"9","author":"Drakaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1758835921996656","DOI":"10.1177\/1758835921996656","article-title":"Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation","volume":"13","author":"Gaucher","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:27:52Z","timestamp":1746332872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":29,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029473","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}